Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by C4 Therapeutics, Inc.

C4 Therapeutics to Host Webcast to Present New Dose Escalation Data from CFT7455 Phase 1 Study in Relapsed/Refractory Multiple Myeloma
From C4 Therapeutics, Inc.
Via GlobeNewswire
Tickers CCCC
C4 Therapeutics Strengthens Board of Directors with Owen Hughes Appointment
From C4 Therapeutics, Inc.
Via GlobeNewswire
Tickers CCCC
C4 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights
From C4 Therapeutics, Inc.
Via GlobeNewswire
Tickers CCCC
C4 Therapeutics Announces Upcoming Data Presentations for CFT8634, an Orally Bioavailable BiDAC™ Degrader in Development for Synovial Sarcoma and SMARCB1-Null Tumors, and CFT7455, an Orally Bioavailable MonoDAC™ Degrader in Development for Multiple
From C4 Therapeutics, Inc.
Via GlobeNewswire
Tickers CCCC
C4 Therapeutics Announces Chief Financial Officer Succession
From C4 Therapeutics, Inc.
Via GlobeNewswire
Tickers CCCC
C4 Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights
From C4 Therapeutics, Inc.
Via GlobeNewswire
Tickers CCCC
C4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From C4 Therapeutics, Inc.
Via GlobeNewswire
Tickers CCCC
C4 Therapeutics Announces FDA Clearance of Investigational New Drug Application for CFT8919, an Orally Bioavailable BiDAC™ Degrader Targeting EGFR L858R for Non-Small Cell Lung Cancer
From C4 Therapeutics, Inc.
Via GlobeNewswire
Tickers CCCC
C4 Therapeutics Appoints Leonard Reyno, M.D., as Chief Medical Officer
From C4 Therapeutics, Inc.
Via GlobeNewswire
Tickers CCCC
C4 Therapeutics and Betta Pharmaceuticals Announce Exclusive Licensing Agreement for the Development and Commercialization in Greater China of CFT8919, an Orally Bioavailable BiDAC™ Degrader of EGFR L858R for NSCLC
From C4 Therapeutics, Inc.
Via GlobeNewswire
Tickers CCCC
C4 Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights
From C4 Therapeutics, Inc.
Via GlobeNewswire
Tickers CCCC
C4 Therapeutics to Participate in the Stifel 2023 Virtual Targeted Oncology Days
From C4 Therapeutics, Inc.
Via GlobeNewswire
Tickers CCCC
C4 Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights
From C4 Therapeutics, Inc.
Via GlobeNewswire
Tickers CCCC
C4 Therapeutics to Present at Two Virtual February 2023 Conferences
From C4 Therapeutics, Inc.
Via GlobeNewswire
Tickers CCCC
C4 Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CFT1946, an Orally Bioavailable BiDAC™ Degrader, in BRAF V600 Mutant Solid Tumors
From C4 Therapeutics, Inc.
Via GlobeNewswire
Tickers CCCC
C4 Therapeutics Announces 2023 Strategic Priorities to Advance Portfolio of Targeted Protein Degradation Medicines
From C4 Therapeutics, Inc.
Via GlobeNewswire
Tickers CCCC
C4 Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
From C4 Therapeutics, Inc.
Via GlobeNewswire
Tickers CCCC
C4 Therapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights
From C4 Therapeutics, Inc.
Via GlobeNewswire
Tickers CCCC
C4 Therapeutics Receives Study May Proceed Letter from U.S. FDA to Initiate Phase 1/2 Clinical Trial of CFT1946, an Orally Bioavailable BiDAC™ Degrader, in BRAF-V600 Mutant Solid Cancers
From C4 Therapeutics, Inc.
Via GlobeNewswire
Tickers CCCC
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.